The efficacy and Safety of non-vItamiN K antaGonist oraL anticoagulants for intermEdiate stroke risk in patients with Atrial Fibrillation (SINGLE AF study)
Not Applicable
Recruiting
- Conditions
- Diseases of the circulatory system
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1800
Inclusion Criteria
Age: 19~80 years old
- CHA2DS2-VASc score 1 for male or 2 for female among nonvalvular atrial fibrillation patients
- Patients who agree to register for this study
- Patients who can be observed for the progress after treatment
Exclusion Criteria
- Severe liver or kidney dysfunction
- Thyroid dysfunction
- Pregnant or breastfeeding women
- Malignant tumors that have not been completely cured
- Severe structural heart disease
- Predicted survival is less than 12 months
- Patients who do not understand the content of the study or disagree with it
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method major bleeding and clinically relevant non-major bleeding
- Secondary Outcome Measures
Name Time Method strokes;systemic embolism;mortality